The possible involvement of microRNAs in preeclampsia and gestational diabetes mellitus

Pillar, Nir; Yoffe, Liron; Hod, Moshe; Shomron, Noam

doi:10.1016/j.bpobgyn.2014.04.021

Cited by 30 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, novel epigenetic studies suggest the involvement of miRNAs in preeclampsia and other gestational pathologies. In silico and in vitro analysis have identified several miRNA-mRNA regulatory mechanisms that may contribute to the pathogenesis of preeclampsia [ 67 , 68 ]. Mayor-Lynn et al provided evidence that preeclamptic placentas show an altered expression of several miRNAs with potential regulatory functions on the expression of MMP-1, MMP-9 and TIMP-3 [ 69 ].…”

Section: Mmps As New Biomarkers and Potential Biological Targets Imentioning

confidence: 99%

New Insights into the Role of Matrix Metalloproteinases in Preeclampsia

Sosa

Flores-Pliego

Espejel-Núñez

et al. 2017

IJMS

View full text Add to dashboard Cite

Preeclampsia is a severe pregnancy complication globally, characterized by poor placentation triggering vascular dysfunction. Matrix metalloproteinases (MMPs) exhibit proteolytic activity implicated in the efficiency of trophoblast invasion to the uterine wall, and a dysregulation of these enzymes has been linked to preeclampsia. A decrease in MMP-2 and MMP-9 interferes with the normal remodeling of spiral arteries at early pregnancy stages, leading to the initial pathophysiological changes observed in preeclampsia. Later in pregnancy, an elevation in MMP-2 and MMP-9 induces abnormal release of vasoactive factors conditioning hypertension. Although these two enzymes lead the scene, other MMPs like MMP-1 and MMP-14 seem to have a role in this pathology. This review gathers published recent evidence about the implications of different MMPs in preeclampsia, and the potential use of these enzymes as emergent biomarkers and biological therapeutic targets, focusing on studies involving human subjects.

show abstract

Section: Mmps As New Biomarkers and Potential Biological Targets Imentioning

confidence: 99%

New Insights into the Role of Matrix Metalloproteinases in Preeclampsia

Sosa

Flores-Pliego

Espejel-Núñez

et al. 2017

IJMS

View full text Add to dashboard Cite

show abstract

“…[10][11][12] The expression of microRNAs has been reported to be associated with pre-eclampsia and GDM. 13 In addition, microRNA-508-3p was upregulated and microRNA-27a, -9, -137, -92a, -33a, -30d, -362-5p and -502-5p were downregulated in placental tissues of GDM, 14 while the expression of microRNA-132, -29a and -222 was significantly downregulated in serum samples of GDM women. 15 Recently, the expression of microRNA-16-5p, -17-5p, -19a-3p, -19b-3p, -20a-5p was found to be upregulated in plasma samples of women at 16-19 weeks of pregnancy.…”

Section: Introductionmentioning

confidence: 97%

“…MicroRNAs are small non‐coding RNA with 18–22 nucleotides, which have been reported to regulate post‐transcriptional gene expression through binding of the translation section ,and lead to either mRNA degradation or translational inhibition . The expression of microRNAs has been reported to be associated with pre‐eclampsia and GDM . In addition, microRNA‐508‐3p was upregulated and microRNA‐27a, ‐9, ‐137, ‐92a, ‐33a, ‐30d, ‐362‐5p and ‐502‐5p were downregulated in placental tissues of GDM, while the expression of microRNA‐132, ‐29a and ‐222 was significantly downregulated in serum samples of GDM women …”

Section: Introductionmentioning

confidence: 99%

Plasma microRNA‐16‐5p, ‐17‐5p and ‐20a‐5p: Novel diagnostic biomarkers for gestational diabetes mellitus

Cao¹,

Jia

Xing³

et al. 2017

J of Obstet and Gynaecol

129

View full text Add to dashboard Cite

show abstract

“…Wander et al found that circulating early-mid-pregnancy miRs are associated with GDM, particularly among overweight/obese women who are pregnant with male offspring [180]. Pillar et al showed that miRs are involved in the pathogenesis of preeclampsia and GDM and have potential as early biomarkers for disease development [54]. Cao et al concluded that plasma mRNA-16-5p, -17-5p and -20a-5p are potential diagnostic biomarkers in GDM [181].…”

Section: Exosomes and Mirs In Gdmmentioning

confidence: 99%

Exosomes Could Offer New Options to Combat the Long-Term Complications Inflicted by Gestational Diabetes Mellitus

Floriano

Willis

Catapano

et al. 2020

Cells

View full text Add to dashboard Cite

Gestational diabetes Mellitus (GDM) is a complex clinical condition that promotes pelvic floor myopathy, thus predisposing sufferers to urinary incontinence (UI). GDM usually regresses after birth. Nonetheless, a GDM history is associated with higher risk of subsequently developing type 2 diabetes, cardiovascular diseases (CVD) and UI. Some aspects of the pathophysiology of GDM remain unclear and the associated pathologies (outcomes) are poorly addressed, simultaneously raising public health costs and diminishing women’s quality of life. Exosomes are small extracellular vesicles produced and actively secreted by cells as part of their intercellular communication system. Exosomes are heterogenous in their cargo and depending on the cell sources and environment, they can mediate both pathogenetic and therapeutic functions. With the advancement in knowledge of exosomes, new perspectives have emerged to support the mechanistic understanding, prediction/diagnosis and ultimately, treatment of the post-GMD outcomes. Here, we will review recent advances in knowledge of the role of exosomes in GDM and related areas and discuss the possibilities for translating exosomes as therapeutic agents in the GDM clinical setting.

show abstract

The possible involvement of microRNAs in preeclampsia and gestational diabetes mellitus

Cited by 30 publications

References 27 publications

New Insights into the Role of Matrix Metalloproteinases in Preeclampsia

New Insights into the Role of Matrix Metalloproteinases in Preeclampsia

Plasma microRNA‐16‐5p, ‐17‐5p and ‐20a‐5p: Novel diagnostic biomarkers for gestational diabetes mellitus

Exosomes Could Offer New Options to Combat the Long-Term Complications Inflicted by Gestational Diabetes Mellitus

Contact Info

Product

Resources

About